(Q37966667)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22156218%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

2011 update of the drug resistance mutations in HIV-1 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22156218%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

0 references

5

Deenan Pillay

2 references

PubMed publication ID

22156218

26 August 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22156218%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

3

Huldrych F Günthard

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22156218%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Victoria A Johnson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22156218%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Vincent Calvez

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22156218%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Roger Paredes

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22156218%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Robert Shafer

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22156218%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Annemarie M Wensing

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22156218%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Douglas D Richman

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22156218%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

1 November 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22156218%20AND%20SRC:MED&resulttype=core&format=json

Topics in antiviral medicine

18 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22156218%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22156218%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22156218%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

156-164

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22156218%20AND%20SRC:MED&resulttype=core&format=json

Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir

18 January 2020

cites work

1 reference

12 December 2020

Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience

1 reference

12 December 2020

Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy

1 reference

12 December 2020

Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial

1 reference

12 December 2020

Broad Nucleoside Reverse‐Transcriptase Inhibitor Cross‐Resistance in Human Immunodeficiency Virus Type 1 Clinical Isolates

1 reference

12 December 2020

The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis

1 reference

12 December 2020

Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients

1 reference

12 December 2020

Update of the drug resistance mutations in HIV-1: 2007.

1 reference

12 December 2020

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

1 reference

12 December 2020

Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease

1 reference

12 December 2020

Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase.

1 reference

12 December 2020

Effect of isolated V118I mutation in reverse transcriptase on response to first-line antiretroviral therapy

1 reference

12 December 2020

Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir

1 reference

12 December 2020

Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase

1 reference

12 December 2020

Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity

1 reference

12 December 2020

Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways

1 reference

12 December 2020

Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118.

1 reference

12 December 2020

Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics

1 reference

12 December 2020

Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates

1 reference

12 December 2020

Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen

1 reference

12 December 2020

Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa

1 reference

12 December 2020

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

1 reference

12 December 2020

Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years

1 reference

12 December 2020

Clinically relevant genotype interpretation of resistance to didanosine

1 reference

12 December 2020

Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine

1 reference

12 December 2020

Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine.

1 reference

12 December 2020

Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis

1 reference

12 December 2020

Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients

1 reference

12 December 2020

Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure

1 reference

12 December 2020

Prediction of abacavir resistance from genotypic data: impact of zidovudine and lamivudine resistance in vitro and in vivo

1 reference

12 December 2020

Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group

1 reference

12 December 2020

Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens

1 reference

12 December 2020

Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score

1 reference

12 December 2020

Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort

1 reference

12 December 2020

Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs

1 reference

12 December 2020

HIV-1 protease mutations and protease inhibitor cross-resistance

1 reference

12 December 2020

Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)

1 reference

12 December 2020

Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients

1 reference

12 December 2020

Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors

1 reference

12 December 2020

Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort

1 reference

12 December 2020

Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients

1 reference

12 December 2020

Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine

1 reference

12 December 2020

Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial

1 reference

12 December 2020

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel

1 reference

12 December 2020

Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41.

1 reference

12 December 2020

Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases

1 reference

12 December 2020

Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine

1 reference

12 December 2020

Genetic correlates of efavirenz hypersusceptibility

1 reference

12 December 2020

HIV-1 reverse transcriptase connection domain mutations: dynamics of emergence and implications for success of combination antiretroviral therapy

1 reference

12 December 2020

Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients.

1 reference

12 December 2020

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.

1 reference

12 December 2020

Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients

1 reference

12 December 2020

Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS).

1 reference

12 December 2020

Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy

1 reference

12 December 2020

Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors

1 reference

12 December 2020

Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level

1 reference

12 December 2020

Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro

1 reference

12 December 2020

Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria

1 reference

12 December 2020

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22156218%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

PubMed publication ID

22156218

1 reference